# Trial of MEDI-507 in CD2-Positive Lymphoproliferative Disease

> **NCT00123942** · PHASE1 · TERMINATED · sponsor: **MedImmune LLC** · enrollment: 31 (estimated)

## Conditions studied

- Lymphoproliferative Disorders

## Interventions

- **DRUG:** MEDI-507

## Key facts

- **NCT ID:** NCT00123942
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-04
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 31 (ESTIMATED)
- **Why stopped:** After review of safety events and have decided that further dose escalation of MEDI-507 as a single agent is not feasible.
- **Last updated:** 2007-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00123942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00123942, "Trial of MEDI-507 in CD2-Positive Lymphoproliferative Disease". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00123942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*